Prophylactic HPV vaccine: «A giant leap for mankind and...» questions for our society!;Vaccin prophylactique anti-VPH: «Un grand pas pour l'humanité et...» des questions pour notre société!

Revue Medicale Suisse

Volumn 2, Issue 84, 2006, Pages 2401-2406

  Gerber, Stefan ^a   Gremlich, Sandrine ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE; PAPILLOMA VIRUS VACCINE;

ANTIBODY TITER; CANCER SCREENING; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG COST; DRUG SAFETY; HUMAN; INFECTION PREVENTION; MEDICAL SOCIETY; NONHUMAN; REVIEW; SEXUAL BEHAVIOR; UTERINE CERVIX CANCER; VIRUS INFECTION; WART VIRUS; ARTICLE; FEMALE;

FEMALE; HUMANS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES;

EID: 33845647575     PISSN: 16609379     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (22)

1. Ferlay J, Bray F, Pisani P, et al. Globocan 2002: Cancer incidence, mortality and prevalence worldwide. IARC Cancer Base No5, version 2.0. Lyon: IARC Press, 2004.
2. Petignat P, Bouchardy C, Sauthier P. Dépistage du cancer du col utérin: situation actuelle et perspectives. Rev Med Suisse 2006;2:1308-12.
3. Franco EL, Duarte-Franco E, Ferenczy A. Cervical cancer: Epidemiology, prevention and the role of human papillomavirus infection. Can Med Assoc J 2001;164:1017-25.
4. * Zur Hausen H. Papillomaviruses causing cancer: Evasion from host-cell control in early events in carcinogenesis. J Natl Cancer Inst 2000;92:690-8.
5. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worlwide. J Pathol 1999;189:12-9.
6. Bosch FX, Lorincz A, Munoz N, et al. The causal relation between human papilloma virus and cervical cancer. J Clin Pathol 2002;55:244-65.
7. ** Munoz N, Bosch X, de Sanjosé S, et al. Epidemiologic Classification of Human Papillomavirus Types Associated with Cervical Cancer. N Engl J Med 2003;348:518-27.
8. de Villiers E, Fauquet C, Brooker T, et al. Classification of papillomaviruses. Virology 2004;324:17-27
9. Da Silva D, Eiben G, Fausch S, et al. Vaccines: Emerging Concepts and Developments. J Cell Physiol 2001;186:169-82.
10. Koutsky LA, Ault K, Wheeler CM, et al. A controlled trial of human papillomavirus type 16 vaccine. N Engl J Med 2002;347:1645-51.
11. Harper D, Franco E, Wheeler C, et al. Sustained efficacy up to 4,5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: Follow up from a randomised control trial. Lancet 2006;367:1247-55.
12. Villa L, Costa R, Petta C, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) L1 virus-like particle vaccine in young women: A randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005;6:271-8.
13. Sherman ME, Lorincz AT, Scott DR, et al. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: A 10-year cohort analysis. J Natl Can Inst. 2003;95:46-52.
14. Bozon M. At what age do women and men have their first sexual intercourse? World comparisons and recent trends. Popul Soc (Paris) 2003;391:1-4.
15. Currie C, Roberts C, Morgan A, et al. Young people's health in context, Health Behaviour in School-aged Children (HSBC) study: International report from the 2001/2002 survey. Health Policy for Children and Adolescents, WHO Report, Copenhagen, 2004; No 4. p. 153-60.
16. Nolan T, Block SL, Reisinger K. Comparaison of the immunogenicity and tolerability of a prophylactic quadrivalent human papillomavirus (HPV) (types 6, 11, 16, 18) L1 virus-like particle (VLP) vaccine in male and female adolescents and young adult women. 23rd Annual Meeting of the European Society for Paediatric Infectious Disease; Valencia, Spain, May 18 2005, Abstract 236.
17. Mao C, Koutsky L, Ault K, et al. Efficacy of Human Papilloma Virus 16 Vaccine to Prevent Cervical Intraepithelial Neoplasia. Obstet Gynecol 2006;107:18-27.
18. Partridge JM, Koutsky LA. Genital human papillomavirus infection in men. Lancet Infect Dis 2006;6:21-31.
19. Office fédéral de la santé publique. Etat janvier 2006, Suppl. VII: Classeur «maladies infectieuses» - Diagnostic et prévention. Plan de vaccination suisse 2006;1-14. http://www.bag.admin. ch/themen/medizin/00682/00685/02112/index.html
20. Brabin L, Roberts SA, Farzaneh F, et al. Future acceptance of adolescent human papillomavirus vaccination: A survey of parental attitudes. Vaccine 2006;24:3087-94.
21. Kennedy D. News on Women's Health. Science 2006;313:273.
22. Risser W, Bortot A, Benjamins L, et al. The epidemiology of sexually transmitted infections in adolescents. Sem Pediatr Infect Dis 2005;16:160-7.